Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
NCT05226923
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
123
Enrollment
INDUSTRY
Sponsor class
Conditions
Bacterial Infections
Interventions
DRUG:
KSP-1007
OTHER:
Placebo:0.9% sodium chloride
DRUG:
Meropenem
Sponsor
Sumitovant Biopharma, Inc.